


UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: March 7, 2024
 Location: Via conference call/Teams

| Agenda Item | Speaker | Recommendation | Conclusions/Recommendations | Vote |
|--|--------------|---|---|------|
| Meeting called to order | G. Shutzberg | 5:02PM EST | | |
| A. Minutes from previous meetings | G. Shutzberg | Review of Minutes from December 14, 2023 | Minutes reviewed, approved | Yes |
| B. Formulary Review - New Drugs | C. Blosser | Akeega | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Blosser | Lodoco | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Blosser | Ojjaara | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Bimzelx | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Fruzaqla | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Iyuzeh | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Blosser | OmvoH | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Blosser | Velsipity | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Blosser | Sohonos | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Jesduvroq | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Epogen | | |
| | | Recommendation: • Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Procrit | | |
| | | Recommendation: • Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Opfolda | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Pombiliti | | |
| | | Recommendation: • Medical Benefit with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Opvee | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Zurzuvae | | |
| | | Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |

| C. Formulary Review - PDL Modifications | C. Blosser | Confirm Review of PDL Modifications Grid | Yes/No | Yes |
|--|------------|--|---|-----|
| | | Recommendation: • Testosterone Gel Pump 1.62% : Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Testosterone cypionate : Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Testosterone enanthate : Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Trientine 250mg : Move to preferred with Dx2Rx across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Amlodipine/ Benazepril : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Amlodipine/ Olmesartan : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Amlodipine/ Valsartan : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Irbesartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Olmesartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Valsartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Mesalamine Capsule 0.375gm ER : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Mesalamine Tablet 1.2gm DR : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Mesalamine Capsule 400mg DR : Move to non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Acyclovir Topical Ointment : Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Uzedy : Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Adalimumab- abdm : Move to preferred with prior authorization in the NY CHIP and NY EPP markets | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Amjevita- high concentration : Move to preferred with prior authorization in the NY CHIP and NY EPP markets | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Cyltezo : Move to non-preferred with prior authorization in the NY CHIP and NY EPP markets | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Amjevita- low concentration : Move to non-preferred with prior authorization in the NY CHIP and NY EPP markets | Motion made, seconded, and carried to accept recommendation | 9:0 |
| D. Formulary Review - New Drugs- Medical | M. Reisman | Confirm Review of New Drugs- Medical Grid | Yes/No | Yes |
| | | Veopoz | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Izervay | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Daxxify | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Aphexda | | |
| | | Recommendation: • Medical benefit across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |

| | | | | |
|---|----------------------|---|---|-----|
| E. Formulary Review - Drugs Evaluated Per Grid | M. Reisman | Apply recommendations as outlined in grid | Motion made, seconded, and carried to accept recommendation | 9:0 |
| F. Clinical Guidelines | M. Reisman | Clinical Guideline Review | | |
| | | Apply New Pharmacy Guidelines | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Continue to Apply Pharmacy Guidelines Requiring Modifications | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Remove Pharmacy Guidelines Requiring Archival | Motion made, seconded, and carried to accept recommendation | 9:0 |
| G. Quality Monitoring | A. Cline/ C. Blosser | Confirm Review of Quality Data | Yes/No | Yes |
| | A. Cline | DUR Review | | |
| | C. Blosser | Drug Recalls – 4th Quarter 2023 | | |
| | C. Blosser | Top 25 Drugs by Spend and Volume – 4th Quarter 2023 | | |
| | C. Blosser | Top 10 Drugs Requested - Approvals and Denials – 4th Quarter 2023 | | |
| | C. Blosser | Grievances and Appeals Data – 4th Quarter 2023 | | |
| | C. Blosser | Inter-Rater Reliability (IRR) – 4th Quarter 2023 • Pharmacists | | |
| H. Additional Comments/Questions | Comment: | Dr. Fitzhugh asked about shortages of ADHD medications; Maria Theys answered, we are handling these shortages on a market to market basis. Jason Hackett stated, there are help desk processes in place at OptumRx to provide override for payment for brand when a member can't get a generic medication during shortages; we also work with our health plan pharmacists to address shortages. Shortages appear to be regional and sporadic; there have also been PDL expansions to accommodate. We have put these processes in place for all drug shortages within the last year and a half, not strictly for ADHD medications. | | |
| Adjournment | G. Shutzberg | | 6:57PM EST | |
| Respectfully Submitted to the Committee, | | | | |
|  | | | | |
| James P. Hancovsky, M.S.I.A., R.Ph. | | | | |
| Chief Pharmacy Officer, UHC C&S | | | | |